Loading…
Loading the latest PSX data…
Loading the latest PSX data…
Haleon Pakistan Limited (HALEON), GlaxoSmithKline Pakistan Limited (GLAXO), Abbott Laboratories (Pakistan) Limited (ABOT): performance, valuation, growth, risk and danioPSX score, side by side.
Add a stock
Growth of Rs 100 from 2025-11-11
Daily closes from PSX end-of-day files, adjusted for bonus shares, right issues and splits (not for cash dividends). KSE-100: official closes where available, otherwise rebuilt from its constituents.
| Measure | HALEONPharmaceuticals | GLAXOPharmaceuticals | ABOTPharmaceuticals |
|---|---|---|---|
| danioPSX score | 65 | 89 | 80 |
| Price and size | |||
| Price | Rs 685.78 | Rs 338.20 | Rs 1,009.87 |
| Today | −0.57% | −0.41% | +0.59% |
| Market cap | Rs 80.3bn | Rs 107.7bn | Rs 98.9bn |
| Traded per day | Rs 20m | Rs 49m | Rs 14m |
| Valuation and dividends | |||
| P/E | 12.3 | 9.8 | 10.7 |
| Dividend yield | 3.6% | 6.1% | 4.4% |
| EPS (last year) | Rs 54.45 | Rs 31.48 | Rs 81.37 |
| Business | |||
| EPS growth | +39.2% | +53.4% | +52.2% |
| Sales growth | +15.9% | +7.7% | +10.6% |
| Net margin | 14.8% | 15.2% | 10.6% |
| Returns | |||
| 1 month | +1.7% | +8.9% | +7.5% |
| 3 months | −7.6% | −1.6% | +9.4% |
| 1 year | −15.7% | −13.9% | −8.1% |
| vs KSE-100, 1 year | -28.8 pts | -27.0 pts | -21.2 pts |
| Trend and risk | |||
| 52-week position | 11% | 28% | 40% |
| RSI 14 | 55 | 65 | 66 |
| RS rank | 27 | 42 | 65 |
| Volatility | 30% | 34% | 30% |
| Beta | 0.86 | 1.05 | 0.77 |
| danioPSX score | |||
| Value | 42 | 69 | 61 |
| Quality | 79 | 81 | 74 |
| Dividend | 45 | 64 | 34 |
| Momentum | 26 | 40 | 59 |
| Safety | 78 | 80 | 76 |
| Shariah-compliant | Yes | Yes | Yes |
Bold marks the best value in each row where higher (or, for P/E and volatility, lower) is clearly better.
A comparison of published numbers, not a recommendation. Share this page: the address holds the stocks. Find more stocks with the screener